CytoDyn Updates

https://www.cytodyn.com/newsroom/press-releases/detail/593/published-paper-indicates-leronlimab-shows-activity-against

Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…

https://youtu.be/GmpJ639gjnk

CytoDyn reveals results from part two of Phase 2 NASH clinical trial CytoDyn Inc CEO Nader Pourhassan talks to Proactive about results from the 350 mg weekly dose of its Phase 2 NASH clinical trial. The Vancouver, British Colu...

https://www.cytodyn.com/newsroom/press-releases/detail/587/cytodyn-submits-protocol-with-the-fda-for-phase-3

CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…